Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK47977 in relapsed or refractory Non-Hodgkin's Lymphoma
NCT07283796Phase 1Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSK47977 in non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
HSK47977
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07283796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283796.